Merck's hepatitis C drug boceprevir gains FDA panel's support

04/27/2011 | Wall Street Journal, The

An FDA panel of outside experts unanimously endorsed the approval of Merck & Co.'s boceprevir, saying the drug candidate marks an advance in the treatment of hepatitis C. The panel affirmed clinical data showing the efficacy of boceprevir in combination with standard medicines ribavirin and pegylated interferon. Merck proposed to commercialize it as Victrelis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN